Compare Stocks: LXEO, BCAX, ABSI, and FBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.71 -7.5%	$9.32	$2.24 ▼ $12.06	$1.49B	2.35	2.59 million shs	2.51 million shs
BCAX Bicara Therapeutics	$23.43 -5.6%	$26.71	$10.30 ▼ $30.99	$1.55B	-0.75	657,497 shs	524,734 shs
FBRX Forte Biosciences	$76.99	$55.18	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
LXEO Lexeo Therapeutics	$4.86 -2.6%	$4.74	$3.99 ▼ $10.99	$398.74M	1.46	930,193 shs	663,603 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	-8.80%	+14.01%	+29.04%	+241.57%
BCAX Bicara Therapeutics	0.00%	-1.97%	-10.81%	+7.72%	+94.93%
FBRX Forte Biosciences	0.00%	+0.09%	+0.01%	+303.72%	+589.87%
LXEO Lexeo Therapeutics	0.00%	-0.41%	+11.72%	-5.45%	+0.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.71 -7.5%	$9.32	$2.24 ▼ $12.06	$1.49B	2.35	2.59 million shs	2.51 million shs
BCAX Bicara Therapeutics	$23.43 -5.6%	$26.71	$10.30 ▼ $30.99	$1.55B	-0.75	657,497 shs	524,734 shs
FBRX Forte Biosciences	$76.99	$55.18	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
LXEO Lexeo Therapeutics	$4.86 -2.6%	$4.74	$3.99 ▼ $10.99	$398.74M	1.46	930,193 shs	663,603 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	-8.80%	+14.01%	+29.04%	+241.57%
BCAX Bicara Therapeutics	0.00%	-1.97%	-10.81%	+7.72%	+94.93%
FBRX Forte Biosciences	0.00%	+0.09%	+0.01%	+303.72%	+589.87%
LXEO Lexeo Therapeutics	0.00%	-0.41%	+11.72%	-5.45%	+0.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.78	Moderate Buy	$13.43	54.17% Upside
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	39.29% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	285.80% Upside

Current Analyst Ratings Breakdown

Latest LXEO, BCAX, ABSI, and FBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/12/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/12/2026	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$16.00 ➝ $23.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	533.83	N/A	N/A	$1.43 per share	6.09
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.08 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$2.87 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A

Latest LXEO, BCAX, ABSI, and FBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
BCAX Bicara Therapeutics	N/A	11.59	11.59
FBRX Forte Biosciences	N/A	10.01	10.01
LXEO Lexeo Therapeutics	N/A	13.89	13.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
BCAX Bicara Therapeutics	N/A
FBRX Forte Biosciences	77.63%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
BCAX Bicara Therapeutics	13.80%
FBRX Forte Biosciences	4.40%
LXEO Lexeo Therapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	210	171.61 million	153.56 million	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable

LXEO, BCAX, ABSI, and FBRX Headlines

Recent News About These Companies

Jupiter Topco LLC Acquires New Shares in Lexeo Therapeutics, Inc. $LXEO

August 30 at 5:04 AM | marketbeat.com

Nantahala Capital Management LLC Takes $6.05 Million Position in Lexeo Therapeutics, Inc. $LXEO

August 29 at 6:39 AM | marketbeat.com

1,489,189 Shares in Lexeo Therapeutics, Inc. $LXEO Acquired by Avoro Capital Advisors LLC

August 27 at 3:12 AM | marketbeat.com

ADAR1 Capital Management LLC Acquires Shares of 1,565,950 Lexeo Therapeutics, Inc. $LXEO

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Takes Position in Lexeo Therapeutics, Inc. $LXEO

August 25, 2026 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 3,345 Shares of Stock

August 20, 2026 | insidertrades.com

Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares

August 19, 2026 | marketbeat.com

Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

August 19, 2026 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO

August 13, 2026 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

August 12, 2026 | marketbeat.com

Lexeo Therapeutics advances gene therapy and gains RMAT status

August 12, 2026 | tipranks.com

Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020

August 12, 2026 | quiverquant.comQ

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

August 12, 2026 | globenewswire.com

Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO

August 12, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

August 10, 2026 | marketbeat.com

Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

August 5, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC

August 3, 2026 | marketbeat.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.06%

July 31, 2026 | aaii.comA

Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Strong-Buy at Chardan Capital

July 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, BCAX, ABSI, and FBRX Company Descriptions

Absci NASDAQ:ABSI

$8.71 -0.71 (-7.54%)

As of 08/28/2026 04:00 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Bicara Therapeutics NASDAQ:BCAX

$23.43 -1.40 (-5.64%)

As of 08/28/2026 04:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Lexeo Therapeutics NASDAQ:LXEO

$4.86 -0.13 (-2.61%)

As of 08/28/2026 04:00 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXEO, BCAX, ABSI, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXEO, BCAX, ABSI, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXEO, BCAX, ABSI, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, BCAX, ABSI, and FBRX Company Descriptions

Absci NASDAQ:ABSI

Bicara Therapeutics NASDAQ:BCAX

Forte Biosciences NASDAQ:FBRX

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXEO, BCAX, ABSI, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXEO, BCAX, ABSI, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXEO, BCAX, ABSI, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, BCAX, ABSI, and FBRX Company Descriptions

Absci NASDAQ:ABSI

Bicara Therapeutics NASDAQ:BCAX

Forte Biosciences NASDAQ:FBRX

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools